b-Catenin is an essential element for the transcriptional activation of target genes in the Wnt signaling cascade and is also a cell adhesion molecule that couples with cadherins. Although plakoglobin (c-catenin), a closely related homologue of b-catenin, is also known to be a cell adhesion molecule, its function as a transcriptional factor has not been revealed in detail. Using a human malignant mesothelioma cell line, NCI-H28, in which we have identified a homozygous deletion of the b-catenin gene, we studied whether plakoglobin has a T-cell factor/ lymphocyte enhancer factor (TCF/LEF) family-dependent transcriptional activity. Transfection with the wildtype plakoglobin expression vector induced accumulation of plakoglobin in the nucleus. Immunoprecipitation assay with cotransfection of plakoglobin and either TCF-4 or LEF-1 detected binding of plakoglobin to TCF-4 or LEF-1. Luciferase reporter assay demonstrated transcriptional activity of the wild-type plakoglobin when transfected with TCF/LEF, although plakoglobin showed less activity than b-catenin. Exogenous plakoglobin was also shown to promote entrance of exogenous b-catenin into the nuclei. Furthermore, small interfering RNA directed against plakoglobin suppressed expression of endogenous plakoglobin and its transcriptional activity, suggesting that endogenous plakoglobin has a weak transcriptional activity. These results suggest that plakoglobin can activate the Wnt signaling cascade directly without interaction of b-catenin, and that plakoglobin has multiple functions as a transcriptional activator and a cell adhesion molecule like b-catenin.
Introduction
Plakoglobin (g-catenin) and b-catenin are homologous proteins with characteristic structural features containing a central armadillo repeat domain flanked by the carboxyl and amino terminal domains, and function in cell-cell junctions when coupled with cadherins (Rubinfeld et al., 1995; Barker and Clevers, 2000) . Plakoglobin is present in adherens junctions and desmosomes where it interacts with desmoglein and desmocollin, whereas b-catenin is present in adherens junctions, where it links cadherin family proteins via acatenin to the actin cytoskeleton (Ben-Ze'ev and Geiger, 1998) .
b-Catenin is also an essential element in the Wnt signaling cascade that plays a critical role in development and tumorigenesis (Morin et al., 1997; Sparks et al., 1998; Polakis, 2000; Moon et al., 2002) . The amino terminal domain of b-catenin contains a highly conserved consensus sequence for phosphorylation by glycogen synthase kinase 3b (GSK3b), while the carboxyl terminal domain is essential for transcriptional activity. In the absence of Wnt signals, GSK3b phosphorylates b-catenin, and the phosphorylated bcatenin is ubiquitinated, resulting in the degradation of b-catenin by proteasomes. Meanwhile, in the presence of Wnt signals, the cytoplasmic pool of b-catenin increases and accumulated b-catenin enters into the nucleus. This results in the formation of complexes with T-cell factor/ lymphocyte enhancement factor (TCF/LEF) family proteins that are capable of transactivating target genes including c-MYC (He et al., 1998) , cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) , the matrix metalloproteinase matrilysin (Crawford et al., 1999) , gastrin (Koh et al., 2000) , and PPARd (He et al., 1999) .
Several lines of evidence have suggested that plakoglobin is also involved in the Wnt signal transduction cascade (Caca et al., 1999; Kolligs et al., 2000; Williams et al., 2000) . Plakoglobin has been shown to bind to LEF-1 and, when overexpressed in mammalian cells, to enhance LEF-1-directed transcription, although a plakoglobin and LEF-1 complex may be very inefficient in binding DNA or in forming a ternary complex containing LEF-1 and the LEF-1-binding DNA sequences (Zhurinsky et al., 2000) . It was also suggested that overexpression of plakoglobin does not directly activate transcription, and that plakoglobin induces transcription indirectly by elevating the level of endogenous b-catenin by blocking degradation of bcatenin in the cytoplasm (Zhurinsky et al., 2000) . However, all these studies were conducted using cell lines with endogenous b-catenin expression, which might interfere in the analysis of the Wnt signal activation that could be regulated by plakoglobin. Furthermore, since a recent study has shown that plakoglobin has a tumor suppressive activity in nonsmall-cell lung cancer through inhibition of b-catenin/ TCF-dependent transcription (Winn et al., 2002) , clarification of how plakoglobin is involved in the Wnt signaling cascade now seems to be needed.
To evaluate the possible functions of plakoglobin in the Wnt signaling cascade, one essential study would be to test its function in b-catenin-deficient cells. Since we have found that a malignant mesothelioma cell line, NCI-H28, has a homozygous deletion of the b-catenin gene (Shigemitsu et al., 2001) , we employed this cell line with transfection of plakoglobin expression vectors, including a putative activating form that was found in a gastric cancer cell line (Caca et al., 1999) . Immunoprecipitation assay showed that plakoglobin binds to TCF/ LEF, and luciferase reporter assay that plakoglobin has TCF/LEF-dependent transcriptional activity. Plakoglobin was also shown to prompt exogenous b-catenin to enter the nuclei. Furthermore, small interfering RNA (siRNA) directed against plakoglobin suppressed the expression of plakoglobin and decreased the transcriptional activity. These findings suggest that plakoglobin has TCF/LEF transcriptional activity independent of bcatenin, although this activity is lower than that of b-catenin.
Results

Expression of exogenous plakoglobin in NCI-H28
We have previously shown with Western blot analysis that a malignant mesothelioma cell line, NCI-H28, has a homozygous deletion of the b-catenin gene, and that these cells express plakoglobin (g-catenin) and Ncadherin, but not E-cadherin (Shigemitsu et al., 2001) . First, to determine whether the deletion of b-catenin affects the cell distribution of endogenous plakoglobin and N-cadherin in NCI-H28 cells, we performed immunofluorescence analysis using anti-plakoglobin and anti-N-cadherin antibodies. Plakoglobin and Ncadherin were found in the cytoplasm and plasma membranes, suggesting that the cellular distribution of these molecules was not altered in the NCI-H28 cells (data not shown). Next, to determine whether other molecules in the Wnt signaling cascades are mutated in NCI-H28 cells, we performed mutational analysis of two genes, APC and AXIN1, which have been shown to be frequently mutated in a variety of human tumors. Sequencing analysis of cDNA generated from NCI-H28 did not detect a mutation of APC between codons 1201 and 1527, where the mutation cluster region is located. Meanwhile, reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing analyses revealed that NCI-H28 expresses alternative splicing forms and nucleotide changes in AXIN1, but they were identical to several EST sequences that were already deposited in the NCBI database. In addition, we found no mutation of plakoglobin in the NCI-H28 cells.
To study whether plakoglobin has transcriptional activity in the NCI-H28 cells, we synthesized the expression vectors with several forms of plakoglobin: a wild-type form (Plak WT), an activating form (Plak S28A), and a form with a deleted C-terminus, which has been reported to be a region critical to transcriptional activity (Plak DC) (Figure 1a , b). We also synthesized the same series of expression vectors with a V5 tag (Plak WT-V5, Plak S28A-V5, and Plak DC-V5). After transfecting them into the NCI-H28 cells, their expression products were confirmed with Western blot analysis using anti-plakoglobin and anti-V5 antibodies ( Figure 1c ). All the constructs were confirmed to translate into proteins of the expected size, which were more abundantly expressed than the endogenous plakoglobin. Meanwhile, we also transfected these constructs into a non-small-cell lung cancer cell line, NCI-H1299, which expresses wild-type b-catenin and plakoglobin, and confirmed that exogenous products were all expressed similarly (data not shown).
Using b-catenin constructs of wild-type form (b-cat WT-V5), an activating mutation form that lacks a serine residue at the GSK3b phosphorylation site (b-cat S37C-V5), and a deletion form (b-cat DC-V5), we previously reported that the activating form was more abundantly expressed than the wild type-form ( Figure 1c ) (Usami et al., 2003) . In the present study, however, we did not detect any apparent difference in the expression levels between Plak WT and S28A mutant, which has been proposed to be an analogous mutation of the activated b-catenin (Figure 1c) . Thus, we suspect that the mutation of plakoglobin in the GSK3b phosphorylation site in the N-terminal domain may not confer greater stability to plakoglobin in this cell line.
Overexpressed plakoglobin accumulates in the nucleus
To evaluate how exogenous plakoglobin is distributed in the cells under the b-catenin-deficient condition, we performed an immunofluorescence analysis of the NCI-H28 cells using anti-plakoglobin antibody (Figure 2 ). In cells transfected with empty vector, endogenous plakoglobin was detected mainly in the cell-cell junction and cytoplasms, but was undetectable in the nuclei. On the other hand, in the cells transfected with Plak WT, a subset of the cells showed strong positive staining in the nuclei, although most of the other cells presented enhanced signals at the cell-cell junction and in the cytoplasm. We also performed immunofluorescence analysis for the H1299 cells, and found nuclear accumulation of plakoglobin in the cells transfected with Plak WT, but not in the cells transfected with the control vector (data not shown).
Plakoglobin forms a complex with TCF/LEF
To determine whether plakoglobin binds to TCF or LEF, we performed an immunoprecipitation assay (Figure 3 ). After the NCI-H28 cells were cotransfected with Plak WT and TCF-4-V5, the cell lysates were immunoprecipitated with the anti-plakoglobin Figure 2 Immunofluorescence analysis. NCI-H28 cells were transfected with empty vector (a) or Plak WT (b) and stained with anti-plakoglobin. Nuclei were stained red with propidium iodide, and stained plakoglobin were colored green Figure 3 Immunoprecipitation of plakoglobin and TCF-4 or LEF-1. NCI-H28 cells were cotransfected with plakoglobin and TCF-4-V5 (lanes 1 and 2) or LEF-1-V5 (lanes 3 and 4). Total lysates were analysed using anti-V5 antibody to confirm expression of TCF-4 or LEF-1 (upper panel). Immunoprecipitation (IP) was performed with anti-plakoglobin antibody (lanes 2 and 4) or with normal mouse IgG (lanes 1 and 3) as negative control, and assayed by Western blot using an HRP-conjugated anti-V5 antibody (lower panel) and a plakoglobin antibody (bottom panel) antibody, and the precipitates were analysed with an HRP-conjugated anti-V5 antibody. A specific band of TCF-4-V5 of the expected size was detected, which indicated that plakoglobin binds to TCF-4. We also prepared cell lysates from the cells that were cotransfected with Plak WT and LEF-1-V5 and similarly performed an immunoprecipitation assay. We detected a specific band of LEF-1-V5, which indicated that plakoglobin also binds to LEF-1 (Figure 3) . Furthermore, we also tested the NCI-H1299 cells with immunoprecipitation assay using the same expression vectors and confirmed the complex formation of plakoglobin with TCF/LEF in these cells (data not shown).
Formation of plakoglobin-TCF-4-DNA complex
To determine whether plakoglobin binds DNA to form a complex, we performed an electrophoretic mobility shift assay (EMSA) (Figure 4 ). At first, we used the NCI-H1299 cells as control, because we found that a much higher efficiency of transfection is induced in NCI-H1299 than in NCI-H28, and that all the exogenous products were easily detectable in NCI-H1299 (data not shown). After the NCI-H1299 cells were transfected with Plak WT and TCF-4-V5, the nuclear extracts were subjected to electrophoresis with a radiolabeled DNA probe containing a TCF/LEF binding site. Nuclear extracts incubated with the optimal DNA probe formed a specific band, which was presumed to be plakoglobin-TCF-4-DNA probe complex. Addition of excess specific competitor (cold optimal DNA probe) decreased the signal of specific bands, whereas addition of nonspecific competitor (cold mutant DNA probe) did not influence the signals. Supershifts were detected in lanes loaded with the protein DNA complex that was incubated with anti-V5 antibody or anti-TCF-4 antibody, indicating that the DNA probe binds to overexpressed TCF-4.
Furthermore, incubation with anti-plakoglobin antibody also induced a supershift, which suggested the formation of a ternary complex of plakoglobin, TCF-4, and DNA. In contrast, incubation with nonspecific IgG did not induce a supershift. Next, we performed EMSA using the NCI-H28 cells. We found the specific signals of the protein-DNA probe complex at the same position as found in NCI-H1299, although the signal intensities were much weaker than those in NCI-H1299. Although we added anti-plakoglobin antibody, anti-V5 antibody, or anti-TCF-4 antibodies in the nuclear extracts, we did not find any supershifts, probably due to lower efficiency of transfection in the NCI-H28 cells (data not shown).
Plakoglobin activates TCF/LEF-dependent transcription without b-catenin
To evaluate whether plakoglobin has TCF/LEF-dependent transcriptional activity in the NCI-H28 cells, we performed luciferase reporter assay using pGL3-OT and pGL3-OF, which are modified constructs of pTOP-FLASH and pFOPFLASH, respectively. First, we confirmed that the b-catenin constructs have transcriptional activity in the NCI-H28 cells, with the S37C being the highest, the wild-type intermediate, and the deletion form the lowest compared to the vector control ( Figure 5 ).
Next, we transfected plakoglobin constructs into the NCI-H28 cells with or without the TCF/LEF constructs. In comparisons with the b-catenin vectors, two of the three types of plakoglobin, Plak WT and Plak S28A (but not Plak DC), showed a weak induction compared with the empty vector. When the plakoglobin vectors were cotransfected with TCF-4 or LEF-1, significant augmentation of the activities was detected, although transfection with TCF-4 or LEF-1 alone produced no activity ( Figure 5 ). Noticeably, compared to the activating form of b-catenin, the mutant form of plakoglobin did not demonstrate enhanced activity. Since S28A mutant did not enhance the protein level either (Figure 1c) , we suspect that an amino-acid change in the GSK3b phosphorylation site does not influence the stability of plakoglobin. In contrast, transcriptional activity was significantly reduced in the carboxyl terminal deletion mutant compared to the wild type under cotransfection with TCF-4 or LEF-1, indicating that the carboxyl terminal of plakoglobin is essential for transcriptional activity. In addition, there was a significant difference in transcriptional activity with TCF-4 and LEF-1 cotransfection, although the underlying mechanism is not clear. We also performed a luciferase reporter assay using the constructs with a V5-epitope and polyhistidine tag, and confirmed the same augmentation of the activities in NCI-H28 (data not shown). Finally, we conducted a luciferase reporter assay in the NCI-H1299 cells, and confirmed that plakoglobin has a transcriptional activity under cotransfection with TCF/LEF (data not shown). 8) and the NCI-H28 cells (lanes 9-11) transfected with Plak WT and TCF-4-V5 were incubated with a radiolabeled optimal probe (lanes 1-7, 9 and 10) or a radiolabeled mutant probe (lanes 8 and 11). Cold optimal probe was added as a specific competitor (lanes 2 and 10), and cold mutant probe was added as a nonspecific competitor (lanes 3). Supershift analysis was performed using normal mouse IgG (lane 4), anti-plakoglobin (lane 5), anti-V5 (lane 6), and anti-TCF-4 (lane7). NS indicates a nonspecific band
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Exogenous plakoglobin promotes nuclear accumulation of b-catenin and shows an additive effect on transcriptional activity
In the b-catenin-deficient cell line, NCI-H28, we showed that plakoglobin has a direct transcriptional activity dependent on TCF/LEF. Since others have also suggested that plakoglobin may have an indirect transcriptional activity through increased nuclear accumulation of b-catenin, we investigated whether plakoglobin induces accumulation of b-catenin in the nuclei of the NCI-H28 cells. After transfection of b-cat WT with or without Plak WT, we counted the cells with nuclear staining of b-catenin and found that the number of stained cells was greater in the cells transfected with Plak WT than without Plak WT (Figure 6a, b) . Furthermore, Western blot analysis demonstrated that nuclear extracts of the cells cotransfected with Plak WT and b-cat WT increased the amount of b-catenin in the nuclei compared with those cotransfected with b-cat WT and empty vector (Figure 6c) . Meanwhile, to test whether the localization of plakoglobin itself can also be influenced by b-catenin, we transfected plakoglobin in the NCI-H28 cells with or without b-catenin. However, we did not find any difference in distribution of plakoglobin under these two conditions, with most plakoglobin being consistently localized in the cytoplasm and a small amount in the nucleus (data not shown). To test whether plakoglobin induces an additive effect on the transcriptional activity of b-catenin, we performed luciferase assay under cotransfection with plakoglobin and b-catenin. We cotransfected the NCI-H28 cells with b-cat WT and Plak WT at minimal amounts to avoid possible competition for transcriptional machinery, and detected an increase of transcriptional activity compared to b-cat WT alone, suggesting that wild-type plakoglobin promoted an additive effect on the transcriptional activity of b-catenin (Figure 6d ). Since the Plak DC, which lacks a direct transcriptional activity, also showed the additive effect, this additive effect was due to an indirect mechanism.
SiRNA for plakoglobin suppresses transcriptional activity in NCI-H28
To test whether endogenous plakoglobin has TCF/LEFfamily-dependent transcriptional activity, we designed siRNA to suppress endogenous expression of plakoglobin. First, to confirm that this plakoglobin siRNA functions effectively, we transfected NCI-H1299 cells with plakoglobin siRNA and detected decreased expression of plakoglobin, to less than 10% that of cells transfected with Tax siRNA (Figure 7a ). Next, we transfected NCI-H28 cells with plakoglobin siRNA and found expression decreased to about half that of cells transfected with Tax siRNA (Figure 7a ). Finally, we performed luciferase assay using NCI-H28 cells after transfection with plakoglobin siRNA, and observed a decrease of activity (Figure 7b ), suggesting that endogenous plakoglobin also has a weak transcriptional activity.
Discussion
It the present study, using a b-catenin-deficient cell line, NCI-H28, we tested whether plakoglobin has transcriptional activity in the Wnt signaling cascade. We found that exogenously expressed plakoglobin accumulates in the nuclei of NCI-H28 cells, that plakoglobin binds to TCF/LEF, and that plakoglobin directly activates TCF/ LEF-dependent transcription without b-catenin. Plakoglobin was also shown to promote nuclear accumulation of b-catenin, suggesting that plakoglobin may also have an indirect transcriptional activity. Furthermore, we found that siRNA for plakoglobin decreased the expression of endogenous plakoglobin and the level of luciferase reporter, indicating that endogenous plakoglobin has a weak transcriptional activity.
Although b-catenin is known to be the key molecule in the Wnt signaling cascade, several lines of evidence have suggested that plakoglobin may also have similar functions to b-catenin in this cascade, and that it is regulated in a similar manner. Like b-catenin, the stability of plakoglobin was shown to be induced by Wnt signals; Axin directly binds to plakoglobin and enhances GSK3b-dependent phosphorylation of plakoglobin, stimulating its degradation (Kodama et al., 1999) . In cells overexpressing plakoglobin, inhibition of the ubiquitin-proteasome pathway was shown to block the decrease in b-catenin level, resulting in accumulation of both b-catenin and plakoglobin in the nucleus (Salomon et al., 1997) . Both plakoglobin and b-catenin were shown to induce neoplastic transformation using a rat kidney epithelial cell line (Kolligs et al., 2000) . Furthermore, it was also shown that the carboxyl terminal domains of both plakoglobin and b-catenin induce transcription, using chimeric constructs of plakoglobin and b-catenin (Williams et al., 2000) .
There has been considerable debate in recent years as to whether plakoglobin transduces Wnt signals via functional interaction with TCF/LEF or whether it acts indirectly by effecting release of b-catenin from adherens junctions or by modulating the activity of the catenin destruction complex (Barker and Clevers, 2000) . All previous studies using cell line models were conducted in environments in which b-catenin was present, and in such environments it would seem difficult to rigorously clarify the function of plakoglobin itself while avoiding the influence of b-catenin. In the present study, we showed that overexpressed plakoglobin accumulates in the nucleus of a b-catenin-deficient cell line, binds to TCF/LEF, and activates transcription. However, our study has also suggested that plakoglobin may have transcriptional activity, albeit much weaker than that of b-catenin. When the NCI-H28 cell line was transfected with equal amounts of b-catenin or plakoglobin constructs, plakoglobin was expressed more abundantly than b-catenin (Figure 1c) . Nevertheless, plakoglobin required cotransfection with TCF-4 or LEF-1 constructs to induce transcription, although the activity of bcatenin was easily detected under the transfection of b-catenin alone. We found that, under cotransfection with plakoglobin and b-catenin in the NCI-H28 cells, plakoglobin induced accumulation of b-catenin in the nuclei, suggesting that the translocation of b-catenin is also an indirect role of plakoglobin for the induction of transcriptional activities.
We found an additive effect of plakoglobin under cotransfection with b-catenin using luciferase reporter assay. Since both wild-type and C-terminus deletion mutant plakoglobins enhanced the transcriptional activity, we speculated that the additive effect is an indirect effect, possibly due to competition for the destruction complex.
To our knowledge, there has been no reported investigation of whether endogenous plakoglobin also has transcriptional activity, and in all previous reports the function of plakoglobin was analysed using overexpressed plakoglobin exogenously transfected. In the present study, using siRNA, we tested the transcriptional activity of plakoglobin in the NCI-H28 cells under a b-catenin-null condition. We detected a decrease in the transcriptional activity, indicating that endogenous plakoglobin itself has a weak TCF/LEF-dependent transcriptional activity. Since NCI-H28 cells also showed low transfection efficiency with siRNA, a stronger decrease in the transcriptional activity might have been detected if the efficiency had been better.
We also tried to test the transcriptional function of plakoglobin by increasing endogenous plakoglobin with lithium chloride (LiCl), which was previously shown to be a specific inhibitor of GSK3b and to increase bcatenin (Klein and Melton, 1996; Stambolic et al., 1996) . Although we did not detect any increase in the amounts of b-catenin in the NCI-H1299 cells after LiCl treatment, neither did we detect an increase in the amount of plakoglobin in NCI-H1299 and NCI-H28 cells (data not shown). These results suggest that plakoglobin is not so greatly influenced by the destruction mechanism, including GSK3b, as is b-catenin.
Genetic mutations of the b-catenin, APC, and AXIN1 genes, which are involved in the Wnt signaling cascade, have been shown in a variety tumors including colon, gastric, and breast cancer (Morin et al., 1997; Rubinfeld et al., 1997; Satoh et al., 2000; Webster et al., 2000; Wong et al., 2001; Clements et al., 2002) . However, activating mutations of plakoglobin seem to occur very infrequently in human malignancies compared to such mutations of b-catenin. One gastric cancer was shown to have a missense mutation at serine 28 of plakoglobin, a potential phosphorylation site (Caca et al., 1999) , but this has been the only report of a mutation of plakoglobin analogous to a putative phosphorylation site of b-catenin thus far. As for mutations at other sites of plakoglobin, a missense mutation at codon 19 causing a threonine to isoleucine substitution and a silent mutation at codon 28 were reported in NCI-H1726 (squamous cell lung carcinoma) and NCI-H1048 (smallcell lung carcinoma), respectively . One of the reasons for the infrequency of plakoglobin mutation in human malignancies may be the weaker contribution of mutated plakoglobin than that of mutated b-catenin to transcriptional activity, which is consistent with a report by other researchers (Williams et al., 2000) . In contrast, plakoglobin was recently proposed to be a potentially novel tumor suppressor protein in a subset of human non-small-cell lung cancers (Winn et al., 2002) . Although they suggested that the inhibition of b-catenin transcriptional activity by exogenous plakoglobin was one of the mechanisms of cell growth inhibition, we suspect that the question of whether plakoglobin has a tumor suppressive function in human malignancy requires further study.
To identify the target genes of plakoglobin, we first performed expression analyses to test whether cyclin D1 and c-MYC, well-known downstream genes of bcatenin, are also induced by transfection of plakoglobin. However, no obvious differences in the expression levels of these genes were found between NCI-H28 cells transfected with empty vector and those cotransfected with plakoglobin and TCF/LEF (data not shown). We suspect that one of the reasons is that the downstream genes of plakoglobin may be different from those of bcatenin. Alternatively, although these genes might have been actually induced when plakoglobin was transfected, it is possible that the assays we employed could not detect the induction since the NCI-H28 cells were extremely resistant to transfection regardless of the various transfection systems we tested that are currently available (data not shown). The lack of detection of the supershift bands of EMSA with the NCI-H28 cells might also be for the same reason.
In summary, we demonstrated that plakoglobin has TCF/LEF-dependent transcriptional activity without the existence of b-catenin using a b-catenin-deficient cell line, NCI-H28, and we consider this cell line to be a useful model to study the functions of plakoglobin in detail under conditions without b-catenin.
Materials and methods
Plasmids
All the inserts of plakoglobin and TCF-4 constructs were generated using RT-PCR amplification with total RNA extracted from normal lung, while LEF-1 constructs were from a colon cancer cell line, SW480. The PCR products of plakoglobin and TCF-4 were cloned into BamHI and XbaI sites, and a PCR product of LEF-1 was cloned into BamHI and EcoRI sites of pcDNA3.1 ( þ ) (V790-20, Invitrogen, Carlsbad, CA, USA) and pcDNA3.1/V5-HisA (V810-20, Invitrogen). As the mutant form of plakoglobin is analogous to activating form of b-catenin, serine-to-alanine substitutions at codon 28 (S28A) were obtained using a method with PCRbased site-directed mutagenesis. The carboxyl terminal deletion mutant (DC) of plakoglobin, which lacks the last 59 amino acids, was produced with a PCR technique. Preparation of bcatenin constructs is described elsewhere (Usami et al., 2003) . All inserts of all constructs were confirmed by sequencing.
pGL3-OT and pGL3-OF for luciferase reporter assay were provided by Dr B Vogelstein. The pGL3-OT promoter contains three TCF/LEF binding sites, whereas pGL3-OF contains mutated inactive binding sites and is a negative control.
Cell lines
NCI-H28 (CRL5820), a malignant mesothelioma cell line, and SW480, a colon cancer cell line, were purchased from the American Type Tissue Culture Collection (ATCC) (Rockville, MD, USA). NCI-H1299, a lung cancer cell line, was a gift from Dr A F Gazdar.
Cell culture and transient transfections
NCI-H28 and NCI-H1299 were cultured in RPMI-1640 (Sigma Aldrich, Irvine, UK) supplemented with 10% fetal bovine serum (Equitech-Bio, Ingram, TX, USA), and 1 Â antibiotic-antimycotic (Invitrogen) at 371C in a humidified incubator containing 5% CO 2 . Transient transfections were done using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's protocols. Six-well tissue-culture plates were used for Western blotting and reporter assay, 100-mm dishes for immunoprecipitation, and 24-well tissue culture plates with cover glasses (Asahi Techno Glass, Funabashi, Japan) in the wells for immunofluorescence.
Western blot analysis
Preparation of total cell lysates and Western blotting were performed as described previously (Sekido et al., 1994) . In brief, subconfluently growing cells were rinsed with phosphatebuffered saline (PBS), lysed in sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 2% 2-mercaptoethanol, and 10% glycerol), and homogenized. In all, 15 mg of total cell lysate protein was subjected to SDSpolyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% nonfat dry milk/PBS, the filters were incubated with a first antibody, washed with PBS, reacted with anti-mouse IgG linked with horseradish peroxidase (NA931, Amersham Biosciences, Buckinghamshire, UK), and detected with ECL or ECL-plus (Amersham Biosciences, Buckinghamshire, UK). The first antibodies used were anti-b-catenin antibody (C19220, Pharmingen/Transduction Laboratories, San Diego, CA, USA), anti-g-catenin antibody (C26220, Pharmingen/ Transduction), anti-V5 antibody (R960-25, Invitrogen), and anti-V5-HRP antibody (R961-25, Invitrogen).
Immunofluorescence staining
Cells were grown on cover glasses in RPMI media for 24 h at 371C. After three washes with PBS, cells were fixed in 4% paraformaldehyde/PBS for 15 min, permeabilized with 0.2% Triton X-100/PBS for 5 min, and preblocked in 5% nonfat dry milk/PBS for 15 min. The slides were then incubated with primary antibody (diluted 1 : 500 in blocking solution) for 1 hour, washed three times with PBS, and incubated with a secondary antibody with an FITC-conjugated anti-mouse antibody (FI-2000, Vector Laboratories, CA, USA) for 30 min. After further washes, the slides were mounted with Vectashield (Vector Laboratories), and cells were examined with fluorescence optics on a confocal microscope, and photographed at a Â 600 magnification.
Immunoprecipitation analysis
Transfected cells were washed twice with PBS and lysed in icecold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1 % Triton X-100) supplemented with one tablet of Complete protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) per 50 ml, 1 mM phenylmethylsulfonylfluoride (PMSF) and 1 mM sodium orthovanadate. The cell lysates were centrifuged at 10 000 g for 30 min to remove cell debris. The supernatants were preincubated with anti-mouse Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and normal mouse IgG (Santa Cruz) for 30 min at 41C, then centrifuged at 1000 g for 5 min to remove the beads. In all, 1 ml of each lysate was incubated with 1 mg of anti-plakoglobin, anti-V5 monoclonal antibodies, or normal mouse IgG (as a negative control) for 2 hours at 41C. After 20 ml of anti-mouse Protein A/G PLUS-Agarose was added, samples were incubated for another hour at 41C. The agarose beads were then washed three times with RIPA buffer and bound proteins were eluted in 20 ml of SDS sample buffer.
EMSA
Cells grown in 60-mm-diameter dishes were transfected with 1.1 mg of Plak WT and 1.7 mg of TCF-4-V5. At 48 h after transfection, nuclear extracts were prepared by the method of Andrews and Faller (1991) . Briefly, after cells were incubated in hypotonic buffer (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl 2 , 10mM KCl, 0.5 mM dithiothreitol, and 0.2 mM PMSF), nuclei were pelleted by centrifugation. Nuclear proteins were then extracted with 30 ml of lysis buffer (20 mM HEPES-KOH, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM PMSF). Binding reaction was performed with Gel Shift Assay Systems (Promega, Madison, WI, USA) according to the manufacturer's protocol. Each sample containing 3 mg nuclear protein and 0.5 ng radiolabelled probe was incubated for 20 min at room temperature. As the optimal DNA probe containing the TCF/LEF binding motif, we used a double-stranded oligonucleotide ACTCTGGTACTGGCCCTTTGATCTTTCTGG. The mutant probe comprised a double-stranded oligonucleotide ACTCTGGTACTGGCCCGGGGATCTTTCTGG (Barker et al., 1999) . For supershift analysis, 0.5 mg of anti-Tcf-4 antibody (clone 6H5-3, #05-511, Upstate Biotechnology, Lake Placid, NY, USA), anti-V5 antibody, anti-plakoglobin antibody or normal mouse IgG was added, and then the mixtures were incubated for another 20 min. The samples were subsequently subjected to nondenaturing polyacrylamide gel electrophoresis.
Luciferase reporter assay
Cells grown in six-well tissue culture plates were transfected with 0.5 mg of one of the catenin constructs, 0.05 mg of the TCF-4 or LEF-1 constructs, 0.15 mg of pGL3-OT or pGL3-OF, and 0.3 mg of pSV-b-galactosidase control vector (Promega). For cotransfection with b-catenin and plakoglobin, we used 0.35 mg of b-cat WT and 0.005 mg of Plak WT or Plak DC. At 48 hours after transfection, reporter gene activity was determined in a luminometer with the Luciferase Assay System (Promega). Luciferase activity was normalized for transfection efficiency by measuring b-galactosidase activity with the b-Galactosidase Enzyme Assay System (Promega).
SiRNA
We designed siRNA for plakoglobin (sense, 5'-GCUGAU CAUCCUGGCCAAUdTdT-3'), which extends between amino acids 303 and 309 of plakoglobin. SiRNA for HTLV-1 Tax (sense, 5'-GAUGGACGCGUUAUCGGCUdTdT-3'), which extends between amino acids 60 and 66, was used as a negative control. Cells grown on 24-well plates were transfected with 40 pmol of double-stranded siRNA using Lipofectamine 2000 (Invitrogen), according to the manufacturer's suggestions. After 24 h, cells were transfected with 0.3 mg of pGL3-OT or pGL3-OF together with 6 ng of phRL-TK vector (Promega) using LipofectAMINE plus reagent, and after an additional 24 h luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
